PT  - JOURNAL ARTICLE
AU  - Koerber, Stefan A.
AU  - Will, Leon
AU  - Kratochwil, Clemens
AU  - Haefner, Matthias F.
AU  - Rathke, Hendrik
AU  - Kremer, Christophe
AU  - Merkle, Jonas
AU  - Herfarth, Klaus
AU  - Kopka, Klaus
AU  - Choyke, Peter L.
AU  - Holland-Letz, Tim
AU  - Haberkorn, Uwe
AU  - Debus, Juergen
AU  - Giesel, Frederik L.
TI  - <sup>68</sup>Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
AID  - 10.2967/jnumed.118.211086
DP  - 2019 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 234--240
VI  - 60
IP  - 2
4099  - http://jnm.snmjournals.org/content/60/2/234.short
4100  - http://jnm.snmjournals.org/content/60/2/234.full
SO  - J Nucl Med2019 Feb 01; 60
AB  - The present study analyzed the impact of 68Ga-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0% and 44.0% of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3%, respectively. Conclusion: 68Ga-PSMA-11 PET/CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.